To evaluate the therapeutic potential of gastrodin in non-SOD1-mutated ALS MNs, PBMCs were collected from a sporadic ALS patient (sALS), i.e., without known ALS mutations on SOD1, TARDBP, c9orf72, VAPB, and FUS, and reprogrammed to iPSCs. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.